Abstract:Abstract Funding Acknowledgements Type of funding sources: Public grant(s) – National budget only. Main funding source(s): National Agency for Research and Development Purpose The increased activity of the sympathetic nervous system is the pathophysiological key of several pathologies, such as hypertension, heart failure, diabetes, etc., the modulation of its activity can improve the management of these diseases and represents an increased scientific interest. Aim Comparatively evaluation of the effects of modulating SNS activity at different levels through various therapeutic approaches on the NYHA functional class of heart failure and physical capacity to exercise in patients with resistant hypertension. Material and method 75 patients with resistant hypertension and heart failure with the preserved ejection fraction were enrolled in the study. All patients for 21 days underwent standardized ambulatory treatment with Losartan 100 mg, Amlodipine 10 mg and Indapamide 1.5 mg, and were subsequently randomized into three equal groups of 25 patients according to treatment supplemented to the previous treatment: group I M - Moxonidine, group II B - Bisoprolol and group III D – renal denervation. Patients were evaluated clinically, echocardiographically and by the 6-minute walking test at baseline, 3 and 6 months. Results The clinical improvement of NYHA class was confirmed by the progressive increase of the distance traveled in the 6 minute walk test. Thus, the groups being comparable according to the distance traveled at the enrollment stage in the study, noted a statistically authentic dynamic starting with 3 months of continuous medication constituting 392.48 ± 14.88 m in the I M group (+ 20.45% from initial values ) versus 359.84 ± 15.15 m in group II B (+ 15.0% of initial values) and 386.08 ± 11.99 m in group III D (+ 24.33% of initial values), p> 0.05. The increase of the distance traveled continued until 6 months of evaluation in all three observation lots with the following values: 416.12 ± 13.50 m (+ 25.06% from the initial) versus 387.80 ± 12.85 m (+ 21.55% from the initial) and 424.28 ± 10.30 m (+ 31.06% from the initial) in lots I M, II B and III D, respectively. Comparative analysis of the dynamics between groups showed a comparable beneficial effect in improving the distance traveled in the 6 minute walk test in groups of patients treated with Moxonidine and Bisoprolol and the superiority of minimally invasive renal denervation treatment over drug treatment, an event notable starting with 3 months of evaluation and maintained until the end of the supervision period. Conclusions Blockade of the sympathetic nervous system at the central level with the selective imidazoline receptor agonist I1 Moxonidine, at the peripheral level by administration of the β1-cardioselective adrenoblocker Bisoprolol or by the minimally invasive method of renal artery denervation resulted in progresive amelioration of NYHA class and increasing physical capacity to exercise, the pharmacological treatment groups showing a comparable effect, but lower than the group of patients undergoing renal denervation.

Clinical Observation on Hypotensive and Left Ventricular Hypertrophy-Reversing Effects by Moxonidine

Comparison of the Efficacy and Tolerance of Moxonidine with Enalapril in Mild to Moderate Essential Hypertension

Effects of Xuezhikang on Ventricular Remodeling in Spontaneously Hypertensive Rats and the Possible Mechanism

A Clinical Observation on Heat-Sensitive Moxibustion for 30 Cases of Stroke

[Clinical Observation on Therapeutic Effect of Suspended Moxibustion on Temperature-Sensitive Acupoints Plus Medication for Chronic Prostatitis].

Observation of Clinical Curative Effect of Heat-sensitive Moxibustion for Chronic Prostatitis with Moxibustion of Different Quantity

Multicentre Clinical Trial on Moxonidine Hydrochloride for Treatment of Hypertension

Effect of Astragalus Membranaceus on Hypertenison and Mechanisms Investigation in Spontaneously Hypertensive Rats

A randomized controlled protocol on the effect of moxibustion on the cardiac function and quality of life in patients with chronic heart failure

Effect of Shenmai Injection on Status of Micro-Inflammation and Left Ventricular Hypertrophy in Hemodialysis Patients

Efficacy and safety of community-based moxibustion for primary hypertension: A randomized controlled trial with patient preference arms

Observation of Curative Effect on Xinmailong Injection in the Treatment of 110 Patients with Chronic Heart Failure

Influences of Jiangyamaijing Solution on Inflammatory Factors and Left Ventricular Remodeling in Rats with Spontaneously Hypertension*

Clinical Research on Xinmailong Injection and Qihong Capsule in the Treatment of Refractory Heart Failure

Clinical Efficacy and Cardiac Function Analysis of Zhigancao Decoction Combined With Metoprolol in the Treatment of Coronary Heart Disease Arrhythmias

Effect of moxibustion at "Xinshu" (BL15) and "Feishu" (BL13) on expression of TRPV1 and CGRP in the myocardial tissue of chronic heart failure rats

A Study of the Relationships Between Angiotensin-Converting Enzyme Gene, Chymase Gene Polymorphisms, Pharmacological Treatment with Ace Inhibitor and Regression of Left Ventricular Hypertrophy in Essential Hypertension Patients Treated with Benazepril

MARRIAGE: A Randomized Trial of Moxonidine Versus Ramipril or in Combination With Ramipril in Overweight Patients With Hypertension and Impaired Fasting Glucose or Diabetes Mellitus. Impact on Blood Pressure, Heart Rate and Metabolic Parameters

Modulation of sympathetic nervous system activity through various therapeutic approaches in patients with resistant hypertension and heart failure with preserved ejection fraction

[Treatment of Vascular Cognitive Impairment by "Huayu Tongluo" Moxibustion]

Moxibustion for Essential Hypertension and Hypertensive Symptoms: A Systematic Review of 18 Randomized Controlled Trials